In some tumors, CRISPR tech was used to knockout B7H3 to serve as a specificity control as well as B7H3 negative hematologic tumors. Tumors were incubated with NK cells with or without B7H3 TriKE. The IL-15 activity of the B7H3 TriKE was measured in proliferation assays. GTB-5550 (a B7H3 TriKE) was developed as a novel dual camelid (cam) TriKE containing wild type IL-15 and comprised of two cam engagers: targeting CD16 on NK cells and B7H3 on multiple solid tumors. As proof of concept, a clinical trial of GTB-3550 (a CD33- targeted Tri-specific Killer Engager (TriKE) in AML) induced endogenous NK cell expansion and activation in refractory AML patients. GT Biopharma hypothesized that targeted delivery of IL-15 to NK cells along with Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) would impart NK cells with specificity to tumor antigens. IL-15, the homeostatic factor for NK cells is being clinically developed but it has little anti-tumor activity alone. Our approach induces activation of NK cells via CD16 and IL-15 while targeting well-known tumor antigens, offering a potentially safer alternative to T-cell related immunotherapy without cytokine release syndrome and neurotoxicity and we expect to submit an Investigational New Drug (IND) application in 2023 in solid tumors,” said Michael Breen, Executive Chairman and Interim CEO of GT Biopharma.” “GT Biopharma’s TriKE platform harnesses the natural killing power of NK cells with protein therapeutics, not NK cell therapy. GTB-5550 gives a robust and NK cell specific proliferation signal compared to IL-15 alone.Highlights of the abstract poster and mini-oral session include: GTB-5550 TriKE is a tri-specific molecule composed of a dual camelid nanobody that binds the CD16 receptor on NK cells, the single chain variable fragment (scFv) of an anti-B7H3 antibody, and human IL-15. GTB-5550 product candidate is in development for the treatment of B7H3 positive solid tumor cancers and multiple myeloma. (the “Company” or “GTB”) ( NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer (NK) cell engager, TriKE® platform, today announced highlights of an accepted abstract titled, “B7H3-Targeted Tri-specific Killer Engagers deliver IL-15 to NK cells but not T cells, and specifically targets solid tumors as a pan-tumor antigen strategy mediated through NK cells,” for poster presentation both virtually at the European Society for Medical Oncology ("ESMO") Congress 2022 being held at the Paris Expo Porte de Versailles from September 9-13, in Paris, France. 12, 2022 (GLOBE NEWSWIRE) - GT Biopharma, Inc. GTB-5550 TriKE In vivo activity in xenogeneic models of human tumor is underway and already validating in vitro studiesīRISBANE, Calif., Sept.GTB-5550 effectively induced NK cell degranulation and interferon gamma production in response to various prostate, brain tumor (atypical rhabdoid/teratoid), HNSCC, multiple myeloma, sarcoma, ovarian, and myeloid malignancies.GTB-5550 specifically targets B7-H3+ cells.GTB-5550 generates a robust and NK cell specific proliferation signal compared to IL-15 alone.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |